PEDIATRICS Vol. 99 No. 3 March 1997, pp. 311-317
Australian Collaborative Trial of Antenatal Thyrotropin-Releasing Hormone: Adverse Effects at 12-Month Follow-up
Received Sep 17, 1996; accepted Nov 4, 1996.
,
From the * Department of Obstetrics and Gynaecology, University
of Adelaide, South Australia 5005, Australia; Department of
Community Medicine, University of Adelaide, Adelaide, South Australia,
5005, Australia; and § Department of Perinatal Medicine, Women's and
Children's Hospital, North Adelaide, South Australia, 5006, Australia.
Objective. The Australian Collaborative Trial of Antenatal Thyrotropin-Releasing Hormone (ACTOBAT) assessed the efficacy of 200 µg of thyrotropin-releasing hormone (TRH) in combination with glucocorticoids in the prevention of neonatal lung disease. This paper reports the 12-month follow-up of the infants from the trial completed in 1994.
Design. This was a double-blinded randomized controlled trial.
Setting. Women were recruited from level 3 perinatal centers throughout Australia.
Participants. Mothers who had not withdrawn from treatment and whose infants were discharged alive (1262 infants). Extensive efforts were made to trace this entire cohort.
Outcome Measures. A questionnaire was mailed to parents for self-completion immediately before their baby's/babies' first birthday. The questionnaire included a checklist to assess sensory, motor, language, and social development, and use of health services.
Results. Milestone scores were developed from items on the follow-up form. Treatment with TRH was associated with an increased risk of motor delay, social delay, fine motor delay, sensory impairment, and early language impairment. No differences were seen between treatment and placebo groups for motor impairment.
Multivariate analyses were performed, adjusting for chronological age, duration of gestation at randomization, time from randomization to delivery, parity, history of perinatal death, history of preterm rupture of the membranes, infant sex, singleton or twin status, maternal age, and maternal blood pressure (systolic and diastolic) at randomization. For the total cohort (N = 1022), treatment with TRH was associated with motor delay (odds ratio [OR], 1.51; 95% confidence interval [CI] 1.11 to 2.05); social delay (OR 1.40; 95% CI 1.01 to 1.95); sensory impairment (OR, 2.00; 95% CI 1.06 to 3.74); severe impairment (OR, 1.75; 95% CI 1.07 to 2.87); and a trend toward motor impairment (OR, 1.50; 95% CI .97 to 2.33), early language impairment (OR, 1.27, 95% CI .90 to 1.79), and fine motor delay (OR, 1.15; 95% CI .83 to 1.60).
There were no differences between the treatment groups in hospital admissions (OR, 1.08; 95% CI .83 to 1.42), doctors' visits (general practitioner OR adj, 1.09; 95% CI .79 to 1.50 or specialist OR adj 1.15; 95% CI .87 to 1.49), respiratory symptoms (OR adj, 1.16; 95% CI .88 to 1.53), or behavioral disturbances (OR adj, .93; 95% CI .71 to 1.21).
Conclusions. Because antenatal administration of TRH is associated with small, consistent deficits in major milestone achievements at 12 months of age, it is essential that additional planned trials make provision for long-term follow-up. Antenatal TRH should only be used in the context of a clinical trial.
Key words: randomized controlled trial, antenatal TRH, follow-up, developmental assessment.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Lim, M. K. Herring, K. H. Leef, J. Getchell, L. E. Bartoshesky, and D. A. Paul Hypothyroxinemia in Mechanically Ventilated Term Infants Is Associated With Increased Use of Rescue Therapies Pediatrics, February 1, 2005; 115(2): 406 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rijken, G. M. S. J. Stoelhorst, S. E. Martens, P. H. T. van Zwieten, R. Brand, J. Maarten Wit, and S. Veen Mortality and Neurologic, Mental, and Psychomotor Development at 2 Years in Infants Born Less Than 27 Weeks' Gestation: The Leiden Follow-Up Project on Prematurity Pediatrics, August 1, 2003; 112(2): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A L Ogilvy-Stuart Neonatal thyroid disorders Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2002; 87(3): F165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Paul, K. H. Leef, J. L. Stefano, and L. Bartoshesky Thyroid Function in Very-Low-Birth-Weight Infants with Intraventricular Hemorrhage Clinical Pediatrics, November 1, 2000; 39(11): 651 - 656. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Brocklehurst, D. Elbourne, and Z. Alfirevic Role of external evidence in monitoring clinical trials: experience from a perinatal trial BMJ, April 8, 2000; 320(7240): 995 - 998. [Full Text]
|
|
|
|
|
|
O. Dammann and A. Leviton Brain Damage in Preterm Newborns: Might Enhancement of Developmentally Regulated Endogenous Protection Open a Door for Prevention? Pediatrics, September 1, 1999; 104(3): 541 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dembinski;, D. A. Paul, K. H. Leff, J. L. Stefano, and L. Bartoshesky Thyroid Function and Adverse Outcome---What Is the Message? Pediatrics, July 1, 1999; 104(1): 129 - 129. [Full Text]
|
|
|
|
 |
|
 T. N. George, O. L. Miakotina, K. L. Goss, and J. M. Snyder Mechanism of all trans-retinoic acid and glucocorticoid regulation of surfactant protein mRNA Am J Physiol Lung Cell Mol Physiol, April 1, 1998; 274(4): L560 - L566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Ballard, P. L. Ballard, A. Cnaan, J. Pinto-Martin, D. J. Davis, J. F. Padbury, R. H. Phibbs, J. T. Parer, M. C. Hart, F. L. Mannino, et al. Antenatal Thyrotropin-Releasing Hormone to Prevent Lung Disease in Preterm Infants N. Engl. J. Med., February 19, 1998; 338(8): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Paneth;, J. E. Hiller, C. A. Crowther, R. R. Haslam, and J. S. Robinson ACTOBAT: 1-Year Follow-up Pediatrics, November 1, 1997; 100(5): 903 - 903. [Full Text]
|
|
|
|
|
|
C. Crowther; and M. C. McCormick The ACTOBAT Debate Pediatrics, September 1, 1997; 100(3): 418 - 418. [Full Text] [PDF]
|
|
|
|
|
|
M. C. McCormick The Credibility of the ACTOBAT Follow-up Study Pediatrics, March 1, 1997; 99(3): 476 - 476. [Full Text] [PDF]
|
|
|
|
|
|
K. Archavachotikul, T. J. Ciccone, M. R. Chinoy, H. C. Nielsen, and M. V. Volpe Pre- and Postnatal Lung Development, Maturation, and Plasticity: Thyroid hormone affects embryonic mouse lung branching morphogenesis and cellular differentiation Am J Physiol Lung Cell Mol Physiol, March 1, 2002; 282(3): L359 - L369. [Abstract] [Full Text] [PDF]
|
|
